The Glioma International Case-Control Study: A Report From the Genetic Epidemiology of Glioma International Consortium

Amirian, E. Susan; Armstrong, Georgina; Zhou, Renke; Lau, Ching C.; Claus, Elizabeth B.; Barnholtz‐Sloan, Jill S.; Il’yasova, Dora; Schildkraut, Joellen; Ali‐Osman, Francis; Sadetzki, Siegal; Johansen, Christoffer; Houlston, Richard S.; Jenkins, Robert B.; Lachance, Daniel H.; Olson, Sara H.; Bernstein, Jonine L.; Merrell, Ryan; Wrensch, Margaret; Davis, Faith G.; Lai, Rose; Shete, Sanjay; Amos, Christopher I.; Scheurer, Michael E.; Aldape, Kenneth; Alafuzoff, Irina; Brännström, Thomas; Broholm, Helle; Collins, Peter; Giannini, Caterina; Rosenblum, Marc K.; Tihan, Tarık; Melin, Beatrice; Bondy, Melissa L.

doi:10.1093/aje/kwv235

Cited by 49 publications

(65 citation statements)

References 30 publications

(29 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Studies participating in GICC are described in Amirian et al 46 and in Supplementary Table 1. Briefly, they comprise 5,189 glioma cases and 3,827 controls that were ascertained through centers in the USA, Denmark, Sweden and the UK.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Genome-wide association study of glioma subtypes identifies specific differences in genetic susceptibility to glioblastoma and non-glioblastoma tumors

Melin¹,

Barnholtz‐Sloan²,

Wrensch³

et al. 2017

Nat Genet

Self Cite

277

375

View full text Add to dashboard Cite

Genome-wide association studies (GWAS) have transformed our understanding of glioma susceptibility, but individual studies have had limited power to identify risk loci. We performed a meta-analysis of existing GWAS and two new GWAS, which totaled 12,496 cases and 18,190 controls. We identified five new loci for glioblastoma (GBM) at 1p31.3 (rs12752552; P = 2.04 × 10−9, odds ratio (OR) = 1.22), 11q14.1 (rs11233250; P = 9.95 × 10−10, OR = 1.24), 16p13.3 (rs2562152; P = 1.93 × 10−8, OR = 1.21), 16q12.1 (rs10852606; P = 1.29 × 10−11, OR = 1.18) and 22q13.1 (rs2235573; P = 1.76 × 10−10, OR = 1.15), as well as eight loci for non-GBM tumors at 1q32.1 (rs4252707; P = 3.34 × 10−9, OR = 1.19), 1q44 (rs12076373; P = 2.63 × 10−10, OR = 1.23), 2q33.3 (rs7572263; P = 2.18 × 10−10, OR = 1.20), 3p14.1 (rs11706832; P = 7.66 × 10−9, OR = 1.15), 10q24.33 (rs11598018; P = 3.39 × 10−8, OR = 1.14), 11q21 (rs7107785; P = 3.87 × 10−10, OR = 1.16), 14q12 (rs10131032; P = 5.07 × 10−11, OR = 1.33) and 16p13.3 (rs3751667; P = 2.61 × 10−9, OR = 1.18). These data substantiate that genetic susceptibility to GBM and non-GBM tumors are highly distinct, which likely reflects different etiology.

show abstract

Section: Methodsmentioning

confidence: 99%

“…Cases had newly diagnosed glioma, and controls had no personal history of central nervous system tumor at the time of ascertainment. Detailed information regarding recruitment protocol is given in Amirian et al 46 . Cases and controls were genotyped using the Illumina Oncoarray according to the manufacturer’s recommendations (Illumina Inc.).…”

Section: Methodsmentioning

confidence: 99%

Genome-wide association study of glioma subtypes identifies specific differences in genetic susceptibility to glioblastoma and non-glioblastoma tumors

Melin¹,

Barnholtz‐Sloan²,

Wrensch³

et al. 2017

Nat Genet

Self Cite

277

375

View full text Add to dashboard Cite

show abstract

“…Details on the GICC study population and methodology have previously been published [9]. Cases were between 18 and 80 years old at diagnosis, were histologically confirmed, and were recruited within 1 year of diagnosis of glioma.…”

Section: Methodsmentioning

confidence: 99%

Glioma-related seizures in relation to histopathological subtypes: a report from the glioma international case–control study

et al. 2018

Self Cite

View full text Add to dashboard Cite

BackgroundThe purpose of this study was to evaluate the distribution of glioma-related seizures and seizure control at the time of tumor diagnosis with respect to tumor histologic subtypes, tumor treatment and patient characteristics, and to compare seizure history preceding tumor diagnosis (or study enrollment) between glioma patients and healthy controls.MethodsThe Glioma International Case Control study (GICC) risk factor questionnaire collected information on demographics, past medical/medication history, and occupational history. Cases from eight centers were also asked detailed questions on seizures in relation to glioma diagnosis; cases (n = 4533) and controls (n = 4171) were also asked about seizures less than 2 years from diagnosis and previous seizure history more than 2 years prior to tumor diagnosis, including childhood seizures.ResultsLow-grade gliomas (LGGs), particularly oligodendrogliomas/oligoastrocytomas, had the highest proportion of glioma-related seizures. Patients with low-grade astrocytoma demonstrated the most medically refractory seizures. A total of 83% of patients were using only one antiepileptic drug (AED), which was levetiracetam in 71% of cases. Gross total resection was strongly associated with reduced seizure frequency (p < 0.009). No significant difference was found between glioma cases and controls in terms of seizure occurring more than 2 years before diagnosis or during childhood.ConclusionsOur study showed that glioma-related seizures were most common in low-grade gliomas. Gross total resection was associated with lower seizure frequency. Additionally, having a history of childhood seizures is not a risk factor ***for developing glioma-related seizures or glioma.

show abstract

“…The combination of technological advancements and collaborative efforts in establishment of consortia such as the Glioma International Case–Control (GICC) study (22) has enabled genotyping of hundreds of thousands of variants in thousands of glioma cases and controls. It is now recognized that a substantial component of glioma genetic risk is explained by combinations of common polymorphisms of modest effect (23), with 27 loci in total identified so far from glioma GWAS (24–33).…”

Section: Introductionmentioning

confidence: 99%

Genome-Wide Association Studies in Glioma

Kinnersley

Houlston

Bondy

2018

Cancer Epidemiology, Biomarkers &Amp; Prevention

Self Cite

View full text Add to dashboard Cite

Since the first reports in 2009, genome-wide association studies (GWAS) have been successful in identifying germline variants associated with glioma susceptibility. In this review, we describe a chronological history of glioma GWAS, culminating in the most recent study comprising 12,496 cases and 18,190 controls. We additionally summarize associations at the 27 glioma-risk SNPs that have been reported so far. Future efforts are likely to be principally focused on assessing association of germline-risk SNPs with particular molecular subgroups of glioma, as well as investigating the functional basis of the risk loci in tumor formation. These ongoing studies will be important to maximize the impact of research into glioma susceptibility, both in terms of insight into tumor etiology as well as opportunities for clinical translation.

show abstract

The Glioma International Case-Control Study: A Report From the Genetic Epidemiology of Glioma International Consortium

Cited by 49 publications

References 30 publications

Genome-wide association study of glioma subtypes identifies specific differences in genetic susceptibility to glioblastoma and non-glioblastoma tumors

Genome-wide association study of glioma subtypes identifies specific differences in genetic susceptibility to glioblastoma and non-glioblastoma tumors

Glioma-related seizures in relation to histopathological subtypes: a report from the glioma international case–control study

Genome-Wide Association Studies in Glioma

Contact Info

Product

Resources

About